PCSA (Processa Pharmaceuticals) Depreciation, Depletion and Amortization: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCSA Processa Pharmaceuticals Inc PCSA
29 GF Score
Price $2.05
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Depreciation, Depletion and Amortization?

Processa Pharmaceuticals PCSA -2.38% 29 Depreciation, Depletion and Amortization is $0.00 Mil as of Jun. 2026. GuruFocus rates PCSA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Processa Pharmaceuticals's depreciation, depletion and amortization for the three months ended in Jun. 2026 was $0.00 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.


Processa Pharmaceuticals  (NAS:PCSA) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Processa Pharmaceuticals Depreciation, Depletion and Amortization Related Terms


Processa Pharmaceuticals Depreciation, Depletion and Amortization Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Depreciation, Depletion and Amortization Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Depreciation, Depletion and Amortization
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.79 0.00 0.00 0.00

Processa Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Depreciation, Depletion and Amortization Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PCSA
29GF Score
Processa Pharmaceuticals Inc PCSA
Depreciation, Depletion and Amortization is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Depreciation, Depletion and Amortization of $0.00 Mil mean?
Processa Pharmaceuticals (PCSA) has a Depreciation, Depletion and Amortization of $0.00 Mil as of Jun. 2026. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Processa Pharmaceuticals.
Is Processa Pharmaceuticals' Depreciation, Depletion and Amortization too high?
Processa Pharmaceuticals' current Depreciation, Depletion and Amortization is $0.00 Mil. Overall, Processa Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Depreciation, Depletion and Amortization compare to EMMA and LIMN?
Processa Pharmaceuticals' Depreciation, Depletion and Amortization of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Depreciation, Depletion and Amortization for a Biotechnology company?
A good Depreciation, Depletion and Amortization depends on the Biotechnology industry context. However, Depreciation, Depletion and Amortization should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Depreciation, Depletion and Amortization mean?
A high Depreciation, Depletion and Amortization can signal that a stock is expensive relative to its fundamentals. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Processa Pharmaceuticals. Processa Pharmaceuticals's current Depreciation, Depletion and Amortization is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Depreciation, Depletion and Amortization of $0.00 Mil. The current Depreciation, Depletion and Amortization is $0.00 Mil. Processa Pharmaceuticals' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Depreciation, Depletion and Amortization calculated?
Depreciation, Depletion and Amortization is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Depreciation, Depletion and Amortization is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
29GF Score

Get the complete analysis for PCSA

Depreciation, Depletion and Amortization is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05
Price